Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials

Cancer

Volumn 91, Issue 9, 2001, Pages 1758-1776

  Follen, Michele ^a   Schottenfeld, David ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cervix; Chemoprevention; Squamous intraepithelial lesions; Surrogate endpoint biomarkers

Indexed keywords

BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOCONJUGATE; ONCOPROTEIN; POLYAMINE; PROTEIN P53; RETINOID; TRACE ELEMENT; TRANSFORMING GROWTH FACTOR;

ARTICLE; CANCER GROWTH; CHEMOPROPHYLAXIS; CYTOPATHOLOGY; DISEASE ACTIVITY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD;

ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMOPREVENTION; CHROMOSOME ABERRATIONS; FEMALE; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; KI-67 ANTIGEN; METALLOENDOPEPTIDASES; NUCLEAR PROTEINS; ONCOGENES; PAPILLOMAVIRIDAE; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 0035339854     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010501)91:9<1758::AID-CNCR1195>3.0.CO;2-1     Document Type: Article

References (167)

1. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials
2. The chemoprevention of cancer: Directions for the future
3. Chemoprevention of cancer
4. Intermediate biomarkers of precancer and their application in chemoprevention
5. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
6. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review
7. Approaches to the development and marketing approval of drugs that prevent cancer
8. Chemoprevention trials and surrogate end point biomarkers in the cervix
9. Human papillomaviruses
10. Yohei Ito Memorial Lecture: Papillomaviruses in human cancers
11. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
12. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials (44165)
13. Optical microscope system for standardized cell measurements and analyses
14. The use of an automated image cytometer for screening and quantitative assessment of cervical lesions in the British Columbia Cervical Smear Screening Programme
15. Image cytometry and chemoprevention in cervical cancer
16. Detection of diagnostic clues in statistical histometry
17. Malignancy associated changes in cervical smears: Systematic changes in cytometric features with the grade of dysplasia
18. DNA ploidy and cytophotometric analysis of cervical intraepithelial neoplasia grade III and invasive squamous cell carcinoma
19. Cytophotometric analysis of corresponding cytological and histological cervical intraepithelial neoplasia grade III specimens
20. DNA-cytometry of progressive and regressive cervical intraepithelial neoplasia
21. DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of α-difluoromethylornithine for cervical intraepithelial neoplasia
22. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials
23. Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine
24. Proliferation in the normal cervix and in preinvasive cervical lesions
25. What is the value of proliferation markers in the normal and neoplastic cervix?
26. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase
27. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia
28. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia
29. The proliferative activity in dysplasia and carcinoma in situ of the uterine cervix analyzed by proliferating cell nuclear antigen immunostaining and silver-binding argyrophilic nucleolar organizer region staining
30. Biological basis of response of cervical squamous cell carcinoma to α-interferon and 13-cis retinoic acid
31. Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining
32. Immuno-histochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papilloma-virus DNA in normal and neoplastic epithelium of the uterine cervix
33. c-myc protein and Ki-67 antigen immunodetection in patients with uterine cervix neoplasia: Correlation of microcytophotometric analysis and histological data
34. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix. Correlation with the histologic grade and human papillomavirus type
35. Detection of p53 protein and Ki-67 proliferation antigen in human papillomavirus (HPV)-positive and HPV-negative cervical lesions by immunohistochemical double-staining
36. A radioautographic analysis of cellular proliferation in dysplasia and carcinoma in situ of the uterine cervix
37. Immunocytochemical detection of S-phase cells in normal and neoplastic cervical epithelium by anti-BrdU monoclonal antibody
38. Sequential dysregulation of proliferation during cervical carcinogenesis
39. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
40. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri
41. Aberrant p53 protein expression in cervical intra-epithelial neoplasia
42. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative turnouts
43. p53 point mutation in HPV negative human cervical carcinoma cell lines
44. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells
45. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
46. Cervical cancer: Papillomavirus and p53
47. p53 polymorphism and risk of cervical cancer
48. p53 polymorphism and risk of cervical cancer
49. p53 polymorphism and risk of cervical cancer
50. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
51. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins
52. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
53. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type
54. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix
55. Expression of cytokine receptors and markers of differentiation in human papillomavirus-infected cervical tissues
56. Studies on pathogenesis of cervical carcinoma based on the analysis of growth and differentiation mechanism of cervical epithelium
57. Patterns of mRNA for epidermal growth factor receptor and keratin B-2 in normal cervical epithelium and in cervical intraepithelial neoplasia
58. Oncogene activation: An informative marker for the human papillomavirus-lesions severity
59. H-ras codon 12 mutation in cervical dysplasia
60. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement
61. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
62. Detection of human papillomavirus genome and analysis of expression of c-myc and Ha-ras oncogenes in invasive cervical carcinomas
63. Search for human papillomavirus, herpes simplex virus and c-myc oncogene in human genital tumors
64. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: Clinical relevance of overexpression in early stages of the cancer
65. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma
66. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix
67. Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract
68. Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract
69. Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus
70. Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells
71. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
72. Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells
73. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
74. The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix
75. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy
76. Early steps in proliferative dysregulation in HPV-associated cervical carcinogenesis
77. Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus
78. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: Evidence for down-regulation in cervical cancer
79. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes
80. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor
81. Epidermal growth factor suppresses insulin-like growth factor binding protein 3 levels in human papillomavirus type 16-immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor 1
82. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an α-difluoromethylornithine chemoprevention trial
83. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers
84. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells
85. Transforming growth factor β regulation of epidermal growth factor receptor in ectocervical epithelial cells
86. Transforming growth factor β1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation
87. Altered expression of transforming growth factor beta-1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix
88. Retinoic acid induces transforming growth factor-β-2 in cultured keratinocytes and mouse epidermis
89. Induction of transforming growth factor β-1 in cervical intraepithelial neoplasia in vivo after treatment with β-carotene
90. Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix
91. Enhanced efficacy of combinations of retinoic acid and retinoid X receptor-selective retinoids and alpha-interferon in inhibition of cervical carcinoma cell proliferation
92. Localization of cellular retinoid-binding proteins in human cervical intraepithelial neoplasia and invasive carcinoma
93. Retinoid status controls the appearance of reserve cells and keratin expression in mouse cervical epithelium
94. Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation
95. Induction of apoptosis by retinoids in human cervical carcinoma cell lines
96. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells
97. Decreased expression of retinoic acid receptors, transforming growth factor β, involucrin, and cornifin in cervical intraepithelial neoplasia
98. Development of difluoromethylornithine (DFMO) as a chemoprevention agent
99. Polyamines as biomarkers of cervical intraepithelial neoplasia
100. Sources of variability in estimating ornithine decarboxylase activity and polyamine contents in human colorectal mucosa
101. Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia
102. Polyamine measurements in the uterine cervix
103. Clinical studies of polyamines and their metabolites
104. Cytokeratin expression in cervical epithelium: An immunohistological study of normal, wart virus-infected and neoplastic tissue
105. Tissue polypeptide antigen and keratins in cervical neoplasia
106. Expression of low molecular weight cytokeratin proteins in cervical neoplasia
107. Expression of cytokeratin No. 19 polypeptide in genital papillomavirus lesions
108. Immunohistochemical study of possible changes in keratin expression during neoplastic transformation of the uterine mucosa
109. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia
110. Expression of the cytokeratin marker CAM 5.2 in cervical neoplasia
111. Cytokeratins in cervical dysplasia and neoplasia: A comparative study of immunohistochemical staining using monoclonal antibodies NCL-5D3, CAM 5.2 and PKK1
112. The dynamics of keratin expression in malignant transformation of cervical epithelium: A review
113. Cytokeratins and the evaluation of tumor differentiation in squamous lesions of the uterine cervix
114. Expression of cytokeratin polypeptides in human papillomavirus (HPV) lesions of the uterine cervix: 1. Relationship to grade of CIN and HPV type
115. Distribution of involucrin in normal and pathological human uterine cervix
116. Immuno-peroxidase staining for involucrin. A potential diagnostic aid in cervicovaginal pathology
117. Involucrin expression in cervical intraepithelial neoplasia: A critical evaluation
118. Retinoic acid suppression of squamous differentiation in human head-and-neck squamous carcinoma cells
119. Cornifin, a cross-linked envelope precursor in keratinocytes that is down-regulated by retinoids
120. Heterogeneous expression of keratin, involucrin, and extracellular matrix among subpopulations of a poorly differentiated human cervical carcinoma: Possible relationships to patterns of invasion
121. Characterization and functional analysis of the expression of vascular adhesion molecules hi human papillomavirus-related disease of the cervix
122. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation
123. Integrin β4 expression in the neoplastic progression of cervical epithelium
124. 1 integrin in normal and pathological squamous epithelia
125. Expression of a novel β1 integrin in the dysplastic progression of the cervical epithelium
126. Jack fruit lectin-specific glycoconjugate expression during the progression of cervical intraepithelial neoplasia: A study on exfoliated cells
127. Distribution of lectin-receptors in normal, dysplastic and neoplastic cervical epithelium
128. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages
129. Lactose-binding lectin expression in human colorectal carcinomas: Relation to tumor progression
130. Differentiation associated modulation of lactoside-binding lectins in cancer cells
131. Expression of CD44 splice variants in normal, dysplastic, and neoplastic cervical epithelium
132. Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium
133. A study of nucleolar organizer regions in cervical intraepithelial neoplasia and human papillomavirus infection
134. Grading cervical dysplasia with AgNORs using a semiautomated image analysis system
135. Micronuclei test in routine smears from uterine cervix
136. The three-group metaphase as a morphologic indicator of high-ploidy cells in cervical intraepithelial neoplasia
137. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma
138. Hypomethylation in cervical tissue: Is there a correlation with folate status?
139. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix
140. Genetic lesion in the carcinogenesis of cervical cancer
141. Allelotype analysis of cervical carcinoma
142. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix
143. Flow cytometric DNA analysis in gynecological oncology
144. DNA content in cervical neoplasia and its relationship to prognosis
145. DNA ploidy patterns in cervical neoplasia grade III, with and without synchronous invasive squamous cell carcinoma
146. Nuclear DNA analysis of koilocytic and premalignant lesions of the uterine cervix
147. Prospective malignancy grading and flow cytometry DNA distribution in biopsy specimens from invasive squamous cell carcinoma of the uterine cervix
148. Quantitative DNA analysis of low grade cervical intraepithelial neoplasia and human papillomavirus infection by static and flow cytometry
149. Flow cytometric classification of biopsy specimens from cervical intraepithelial neoplasia
150. Studies of DNA content in cervical intraepithelial neoplasia by cytologic and histologic flow cytometry
151. Flow cytometric analysis of DNA content in cervical lesions
152. DNA level and stereologic estimates of nuclear volume in squamous cell carcinomas of the cervix. A comparative study with analysis of prognostic impact
153. Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions
154. Matrix metalloproteinases and carcinogenesis
155. Nuclear matrix proteins and their potential applications to diagnostic pathology
156. The association of HPV 16 DNA with specific nuclear matrix proteins of normal and cervical carcinoma cell
157. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: Biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining
158. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation
159. Proteolytic activity in extracts of invasive cervical carcinoma and precursor lesions
160. Immunohistochemical detection of metallothionein and MIB1 in uterine cervical squamous lesions
161. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
162. Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions
163. Telomerase activity and human papillomavirus (HPV) infection in human uterine cervical cancers and cervical smears
164. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix
165. BCL-2 immunoreactivity increases with severity of CIN: A study of normal cervical epithelia, CIN, and cervical carcinoma
166. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions
167. Enhanced expression of anti-apoptotic proteins in human papilloma-virus-immortalized and cigarette smoke condensate-transformed human endocervical cells: Correlation with resistance to apoptosis induced by DNA damage